About
Periodic safety update report single assessments (PSUSAs) are single assessments of related periodic safety update reports (PSURs) for active substances contained in medicines authorised in the European Union (EU). A PSUR is a pharmacovigilance report submitted regularly by a marketing-authorisation holder at defined time points following a medicine's authorisation.
Key facts
- Active substance(s) in scope of the PSUSA procedure
- moxifloxacin (systemic use)
- Procedure number
- PSUSA/00009231/202305
- Regulatory outcome
- Variation
Documents
Moxifloxacin (systemic use) : List of nationally authorised medicinal products - PSUSA/00009231/202305
English (EN) (238.4 KB - PDF)
Moxifloxacin (systemic use) : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00009231/202305
English (EN) (161.51 KB - PDF)
български (BG) (174.59 KB - PDF)
español (ES) (162.1 KB - PDF)
čeština (CS) (164.48 KB - PDF)
dansk (DA) (162.99 KB - PDF)
Deutsch (DE) (166.74 KB - PDF)
eesti keel (ET) (153.92 KB - PDF)
ελληνικά (EL) (166.04 KB - PDF)
français (FR) (164.21 KB - PDF)
hrvatski (HR) (162.18 KB - PDF)
íslenska (IS) (163.28 KB - PDF)
Gaeilge (GA) (157.69 KB - PDF)
italiano (IT) (160.33 KB - PDF)
latviešu valoda (LV) (203.65 KB - PDF)
lietuvių kalba (LT) (162.75 KB - PDF)
magyar (HU) (199.55 KB - PDF)
Malti (MT) (173.06 KB - PDF)
Nederlands (NL) (167.71 KB - PDF)
norsk (NO) (160.09 KB - PDF)
polski (PL) (166.11 KB - PDF)
português (PT) (159.8 KB - PDF)
română (RO) (255.65 KB - PDF)
slovenčina (SK) (200.37 KB - PDF)
slovenščina (SL) (164.51 KB - PDF)
Suomi (FI) (156.96 KB - PDF)
svenska (SV) (161.37 KB - PDF)